Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines
Joachim Alexandre(Government of the United States of America), Franck Thuny(Assistance Publique Hôpitaux de Marseille), Stéphane Éderhy, Jennifer Cautela(Hôpital Nord), Stéphane Champiat(The University of Texas MD Anderson Cancer Center), Laure Farnault(Aix-Marseille Université), Alain Cohen‐Solal(Inserm), Charles Dolladille(Inserm), Joe‐Elie Salem(Inserm), Fabrice Barlési(Hôpital Nord), Ghandi Damaj(Université de Caen Normandie), Aude Charbonnier(Institut Paoli-Calmettes), Ariel Cohen(3D Biomatrix (United States)), Mariana Mirabel
Cited by 298
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
2023 ESC Guidelines for the management of endocarditis
|European Heart Journal|2023|1.6k
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
|Clinical Cancer Research|2016|1.2k